Published in J Immunol on June 15, 2009
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A (2010) 2.46
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice. Arthritis Rheum (2012) 2.16
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis. Clin Immunol (2017) 1.39
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res (2014) 1.10
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis. Bioorg Med Chem (2010) 1.05
IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol (2014) 0.94
IDO2 in Immunomodulation and Autoimmune Disease. Front Immunol (2014) 0.92
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy (2010) 0.91
Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Immunology (2014) 0.89
Pathogenic antibodies are active participants in spinal cord injury. J Clin Invest (2009) 0.86
Systemic treatment with CpG-B after sublethal rickettsial infection induces mouse death through indoleamine 2,3-dioxygenase (IDO). PLoS One (2012) 0.85
A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology (2012) 0.84
Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients. Clin Rheumatol (2011) 0.81
B Cell-Intrinsic IDO1 Regulates Humoral Immunity to T Cell-Independent Antigens. J Immunol (2015) 0.80
Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networks. Sci Rep (2015) 0.79
Suppression of humoral immune response to hepatitis B surface antigen vaccine in BALB/c mice by 1-methyl-tryptophan co-administration. Daru (2011) 0.78
Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis. Int J Tryptophan Res (2013) 0.77
Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression- and autoimmunity-associated genes. Orphanet J Rare Dis (2014) 0.77
1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity (2014) 0.77
The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth. EPMA J (2010) 0.77
IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. J Immunol (2016) 0.76
IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity. Clin Med Insights Pathol (2016) 0.75
Indoleamine 2,3-Dioxygenase Is Dispensable for The Immunomodulatory Function of Stem Cells from Human Exfoliated Deciduous Teeth. Cell J (2016) 0.75
Plasma kynurenic acid concentration in patients undergoing cardiac surgery: effect of anaesthesia. Arch Immunol Ther Exp (Warsz) (2014) 0.75
The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. Cancer Res (2017) 0.75
B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury. Neurotherapeutics (2016) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 9.80
Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol (2007) 8.47
Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2007) 6.67
Organ-specific disease provoked by systemic autoimmunity. Cell (1996) 6.44
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum (1999) 6.39
IL-10: the master regulator of immunity to infection. J Immunol (2008) 6.11
Rheumatoid arthritis. Cell (1996) 6.01
Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science (2002) 5.82
From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 5.38
Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 5.26
Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science (1999) 4.97
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum (2004) 4.58
Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol (2001) 4.39
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol (2006) 3.84
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
T cell apoptosis by tryptophan catabolism. Cell Death Differ (2002) 3.07
4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med (2004) 3.01
The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol (2006) 2.98
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem (1978) 2.78
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol (2007) 2.44
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol (2004) 2.30
Tryptophan and the immune response. Immunol Cell Biol (2003) 2.26
1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys (1991) 2.24
Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol (2001) 2.23
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol (2005) 2.18
Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis (1993) 2.05
Genetic influences on the end-stage effector phase of arthritis. J Exp Med (2001) 1.99
Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology (2003) 1.91
Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol (2008) 1.72
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer (2006) 1.71
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol (2002) 1.69
Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol (2002) 1.67
A crucial role for macrophages in the pathology of K/B x N serum-induced arthritis. Eur J Immunol (2005) 1.65
Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol (1993) 1.65
A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med (2003) 1.62
Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A (1978) 1.60
Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum (2007) 1.52
Tryptophan catabolism and T cell responses. Adv Exp Med Biol (2003) 1.34
The K/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol Med (2007) 1.30
Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol (2003) 1.29
A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene (2007) 1.28
Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci U S A (2008) 1.22
Despite ubiquitous autoantigen expression, arthritogenic autoantibody response initiates in the local lymph node. Proc Natl Acad Sci U S A (2002) 1.21
Interleukin-4 can be a key positive regulator of inflammatory arthritis. Arthritis Rheum (2005) 1.18
Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol (2005) 1.17
Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J Rheumatol (2003) 1.15
Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes (2006) 1.14
Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis Res Ther (2007) 1.09
Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol (2007) 0.99
Increased number and function of FoxP3 regulatory T cells during experimental arthritis. Arthritis Rheum (2008) 0.96
Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.95
CD4+CD25+ regulatory T cells selectively diminish systemic autoreactivity in arthritic K/BxN mice. Mol Cells (2008) 0.87
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice. Arthritis Rheum (2012) 2.16
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity (2002) 1.89
DNA double-strand breaks activate a multi-functional genetic program in developing lymphocytes. Nature (2008) 1.88
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2006) 1.81
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther (2003) 1.46
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry (2006) 1.35
Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol (2003) 1.26
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol (2010) 1.24
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells. J Exp Med (2004) 1.20
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem (2008) 1.18
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther (2002) 1.18
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta (2008) 1.12
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res (2007) 1.10
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem (2008) 1.07
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res (2005) 1.04
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets (2005) 1.02
RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 1.02
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res (2003) 1.00
The MAPK scaffold kinase suppressor of Ras is involved in ERK activation by stress and proinflammatory cytokines and induction of arthritis. J Immunol (2006) 0.99
Cancer: Why tumours eat tryptophan. Nature (2011) 0.99
IDO recruits Tregs in melanoma. Cell Cycle (2009) 0.98
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res (2011) 0.97
Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochem Biophys Res Commun (2005) 0.96
Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene (2003) 0.96
AACR Cancer Progress Report 2013. Clin Cancer Res (2013) 0.95
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther (2010) 0.94
Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol (2008) 0.93
Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Res (2008) 0.93
A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci (2010) 0.93
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy (2010) 0.91
RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem (2011) 0.90
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 0.89
Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther (2011) 0.89
Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res (2002) 0.89
Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem (2003) 0.89
Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res (2007) 0.89
CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. J Radiat Oncol (2013) 0.88
Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther (2007) 0.86
High affinity glycosaminoglycan and autoantigen interaction explains joint specificity in a mouse model of rheumatoid arthritis. J Biol Chem (2008) 0.85
RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res (2012) 0.85
Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro. Toxicol In Vitro (2012) 0.84
RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nat Commun (2013) 0.84
Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res (2004) 0.83
hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene (2003) 0.83
Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biol Ther (2005) 0.82
The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Dev Biol (2013) 0.82
Genomic profiling of miRNAs in two human lens cell lines. Curr Eye Res (2010) 0.82
Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene (2003) 0.82
Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One (2009) 0.81
Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther (2004) 0.81
mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biol Ther (2007) 0.80
Elevated ornithine decarboxylase levels activate ataxia telangiectasia mutated-DNA damage signaling in normal keratinocytes. Cancer Res (2008) 0.80
B cell anergy and systemic lupus erythematosus. Curr Dir Autoimmun (2003) 0.80
A bioactive probe of the oxidative pentose phosphate cycle: novel strategy to reverse radioresistance in glucose deprived human colon cancer cells. Toxicol In Vitro (2012) 0.79
Altered apoptotic responses in neurons lacking RhoB GTPase. Eur J Neurosci (2011) 0.79
RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. Am J Pathol (2010) 0.79
Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course. Am J Pathol (2009) 0.79